GLP-1 Qualifications: How Eligibility Is Determined

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, where we connect GLP-1 science, weight-management protocols, and the genetics beneath every metabolic choice. Browse all Peptides & GLP-1 education.

When people ask about "GLP-1 qualifications," they are really asking who a GLP-1 receptor agonist is for and how a provider decides. Eligibility is not a self-serve checklist; it is a match between your clinical picture and the FDA-approved indication printed on a specific product's label. This overview explains how that judgment is made and links to deeper reads in the Education Hub.

What decides eligibility

Prescribing follows the brand's FDA-approved indication. The same molecule sold under a different brand is not automatically interchangeable for coverage purposes, so eligibility is tied to the exact product and the indication it carries. A licensed prescriber confirms that your situation matches that indication before writing a prescription.

What GLP-1 receptor agonists are used for

FDA-approved indications across the class include type 2 diabetes (most compounds), chronic weight management (Wegovy, Saxenda, Zepbound), cardiovascular risk reduction in type 2 diabetes (several products), and obstructive sleep apnea in adults with obesity (Zepbound, 2024). Which indication applies to you is exactly what a provider weighs when judging eligibility.

How the medications work

GLP-1 receptor agonists engage the GLP-1 receptor across the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and strengthening satiety signaling. GIP/GLP-1 dual agonists such as tirzepatide add engagement of the GIP receptor, a second incretin mechanism. Weekly or daily dosing, depending on the compound, sustains that receptor engagement.

The shared safety profile

Gastrointestinal symptoms, nausea, vomiting, diarrhea, and constipation, are the most commonly reported effects and are usually most pronounced during titration. Every FDA-approved compound in the class carries the boxed warning for thyroid C-cell tumor risk seen in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the setting of dehydration. This safety context is part of any eligibility discussion.

Cost and access considerations

Manufacturer list prices for FDA-approved branded products typically run $800 to $1,600 per month at U.S. list as of April 2026. What you actually pay depends on insurance coverage, the FDA indication on the prescription, savings-card eligibility, and whether a compounded alternative through a licensed 503A pathway is available. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral.

Where genetics inform the picture

Eligibility answers whether a medication fits your indication; genetics describe the metabolic terrain underneath. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1, appetite regulation, and energy balance. It never predicts your response to a specific drug. For background, see What Is GLP-1? and GLP-1 Drugs.

Why eligibility is not the whole story

Meeting an indication is a threshold, not a recommendation. A prescriber weighs eligibility alongside your history, other medications, tolerance for gastrointestinal effects, and your goals before anyone concludes a GLP-1 receptor agonist is the right step. Two people can both fit the same FDA-approved indication and still reach different decisions, because eligibility answers whether a door is open, not whether walking through it serves your situation. That is why the label criteria are a starting point for a conversation rather than a verdict on their own.

It also explains why a genetic snapshot and a clinical evaluation answer different questions. Eligibility is clinical and indication-based; the genetic layer describes underlying biology. Neither replaces the other, and both can inform a more complete discussion with your provider.

A useful way to frame it is that eligibility opens the conversation and the rest of the evaluation shapes it. Your provider is not only checking a box against an indication; they are deciding, with you, whether this class fits the fuller picture of your health, your other treatments, and what you are trying to achieve.

Frequently Asked Questions

How is eligibility for a GLP-1 decided?

A licensed prescriber matches your clinical picture to the FDA-approved indication on a specific product's label. Because the same molecule under a different brand is not automatically interchangeable for coverage, eligibility is tied to the exact product and its indication rather than a general self-assessment.

What conditions are GLP-1 receptor agonists approved for?

Across the class, FDA-approved indications include type 2 diabetes, chronic weight management, cardiovascular risk reduction in type 2 diabetes, and, for Zepbound, obstructive sleep apnea in adults with obesity as of 2024. Your prescriber determines which approved indication applies to your situation.

What safety factors affect who should use one?

The class carries a boxed warning for thyroid C-cell tumor risk seen in rodent studies, plus rare risks of pancreatitis, gallbladder disease, and kidney injury with dehydration. These, along with your personal and family history, are part of the eligibility conversation with a qualified provider.

Does the genetic test determine if I qualify?

No. The Precision Peptide Genetic Test does not determine eligibility and does not predict response to any medication. It analyzes pathway-level variants in genes such as FTO, MC4R that shape baseline metabolic biology, giving you and your provider added context alongside the clinical evaluation.

This guide lives in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.